Support: 888-992-3836
Copyright © 2023 InvestorsHub Inc.
Replies to post #32175 on Ariad Pharmaceuticals Inc fka ARIA
Whosetosay
07/12/13 9:08 PM
#32176 RE: jaybe #32175
iandy
07/13/13 12:57 AM
#32182 RE: jaybe #32175
"Bafetinib (INNO-406) does not sufficiently cross intact or disrupted blood-brain barrier, and therefore, systemic administration of bafetinib is not recommended when investigating this drug as a treatment for brain tumours."
Our studies reveal that INNO-406 is capable of preventing the progression of dopaminergic neuronal damage in a toxin-induced C57 mouse model of PD.